ArticleArthritis care & research2026
Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveHydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long-term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our retrospective longitudinal inception LN cohort to examine the time-varying effects of HCQ on kidney function decline in LN.
methodsWe analyzed retrospective data from an incident biopsy-proven LN cohort. Creatinine values at LN diagnosis through the last follow-up were abstracted to find the estimated glomerular filtration rate (eGFR). Using HCQ exposure as a time-dependent covariate, we examined associations between HCQ exposure and sustained eGFR decline ≥30% and ≥40%. We also calculated an annual eGFR slope decline by HCQ exposure using linear mixed-effects analysis.
resultsAmong 209 patients, 33% and 23% experienced eGFR decline ≥30% and ≥40% over time. Time-varying HCQ exposure was associated with a 60% and 62% lower risk of eGFR decline of ≥30% or ≥40%, after adjusting for propensity scores. A 77% lower risk of eGFR decline was noted in patients with chronic kidney disease (CKD) stage ≥3 with HCQ. HCQ exposure reduced the annual eGFR slope decline by 5.12 and 3.17 mL/min/1.73 m
conclusionHCQ use was associated with early and long-term benefits on kidney function in LN, including those with CKD stage ≥3. Universal HCQ use should be encouraged in LN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.